Equities analysts expect that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will report ($0.12) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Cyclacel Pharmaceuticals’ earnings. Cyclacel Pharmaceuticals posted earnings of ($0.50) per share during the same quarter last year, which would indicate a positive year over year growth rate of 76%. The firm is expected to issue its next earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that Cyclacel Pharmaceuticals will report full-year earnings of ($0.43) per share for the current year. For the next year, analysts anticipate that the business will post earnings of ($0.37) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings data on Monday, May 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01.
CYCC has been the topic of a number of analyst reports. Zacks Investment Research cut Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 6th. ValuEngine upgraded Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, HC Wainwright reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Thursday, March 29th.
NASDAQ:CYCC traded up $0.01 during trading hours on Thursday, reaching $1.45. 28,700 shares of the company traded hands, compared to its average volume of 150,714. Cyclacel Pharmaceuticals has a 1-year low of $1.28 and a 1-year high of $4.52.
A number of large investors have recently made changes to their positions in CYCC. Virtu Financial LLC grew its holdings in Cyclacel Pharmaceuticals by 69.5% during the 4th quarter. Virtu Financial LLC now owns 199,464 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 81,820 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Cyclacel Pharmaceuticals during the 4th quarter valued at $108,000. Finally, Two Sigma Investments LP acquired a new stake in Cyclacel Pharmaceuticals during the 4th quarter valued at $122,000. Hedge funds and other institutional investors own 4.68% of the company’s stock.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.